Media Articles Related to Trelstar (Triptorelin)
Radiation Ups Survival in Prostate Cancer, but Not Low Risk
Source: Medscape Hematology-Oncology Headlines [2015.07.24]
Improved survival was seen in intermediate- and high-risk disease, but not in patients with low-risk prostate cancer.
Medscape Medical News
Study seeks newly diagnosed prostate cancer patients and caregivers to measure impact of evidence-based educational materials
Source: Caregivers / Homecare News From Medical News Today [2015.07.24]
A study funded by the Patient-Centered Outcomes Research Institute (PCORI) and conducted by researchers at Moffitt Cancer Center seeks participants to determine the effectiveness of educational...
Bavarian Nordic announces initiation of NCI-sponsored phase 2 study of PROSVAC in patients with localized prostate cancer
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.07.24]
Bavarian Nordic A/S has announced that the first patient has been enrolled in a new phase 2 clinical study of PROSTVAC, the Company's active prostate cancer immunotherapy candidate.
Prostate cancer - University of York scientists discover why some tumours are resistant to radiotherapy
Source: Genetics News From Medical News Today [2015.07.24]
Scientists at the University of York believe they have identified how some tiny regulatory molecules in cells can make prostate cancers resistant to radiotherapy.
Common side effect of radiation treatment for prostate cancer
Source: Medical Devices / Diagnostics News From Medical News Today [2015.07.23]
Factoring in anatomy and the radiation therapy dose can help doctors predict a prostate cancer patient's risk of suffering from rectal bleeding as a side effect of therapy, and tailor treatment to...
Published Studies Related to Trelstar (Triptorelin)
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. [2011.07.20]
CONTEXT: Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available. OBJECTIVE: To determine the effect of the temporary ovarian suppression obtained by administering the gonadotropin-releasing hormone analogue triptorelin during chemotherapy on the incidence of early menopause in young patients with breast cancer undergoing adjuvant or neoadjuvant chemotherapy... CONCLUSION: The use of triptorelin-induced temporary ovarian suppression during chemotherapy in premenopausal patients with early-stage breast cancer reduced the occurrence of chemotherapy-induced early menopause. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00311636.
A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. [2011.07]
PURPOSE: To compare the role of an aromatase inhibitor (letrozole) with a GnRH agonist (triptorelin) versus case control on the pregnancy rate and recurrence of symptoms and signs in patients with endometriosis... CONCLUSION: Pregnancy rate and endometriosis recurrence rate are comparable among the 3 groups.
Synchronization of ovulation and fertility in weaned sows treated with intravaginal triptorelin is influenced by timing of administration and follicle size. [2011.01.15]
A 100 mug dose of triptorelin was tested for synchronizing ovulation in sows. In Experiment 1, conducted in April through June, sows (n = 125) were assigned to Control (untreated), TG-96 (Triptorelin Gel (TG) given intravaginally at 96 h post-weaning), or TG-E (given intravaginally at estrus)... However, ovulation induction and timed AI success may benefit from an approach that ensures sows have adequate follicle development at time of treatment.
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. [2010.01]
OBJECTIVE: To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas.
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. [2009.01.08]
OBJECTIVE: To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas.Rapid onset of action and avoidance of initial gonadotropin flare with an aromatase inhibitor may be advantageous for short-term management of women with myomas of any size who are to be managed transiently and who wish to avoid surgical intervention, specifically women with unexplained infertility having uterine myoma.
Clinical Trials Related to Trelstar (Triptorelin)
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg [Recruiting]
The purpose of this study is to demonstrate the pharmacodynamic equivalence of triptorelin
pamoate (Pamorelin® LA 11. 25 mg), applied either IM or SC, in terms of the area under the
curve [AUC1-85day] for serum testosterone in patients with advanced prostate cancer.
Efficacy, Safety, and PK of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty [Recruiting]
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22. 5 mg
6-month formulation in 44 patients suffering from central precocious puberty. The null
hypothesis of the study is that the proportion of patients achieving LH suppression to
prepubertal levels at Month 6 is 80%.
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer [Recruiting]
The study will investigate the efficacy, pharmacokinetics and safety of triptorelin embonate
22. 5 mg 6-month formulation administered by subcutaneous injections in patients with
Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty [Recruiting]
The purpose of the study is to assess the efficacy of triptorelin 11. 25 mg pamoate in the
delay of premature onset of puberty in girls less than 9 years and boys less than 10 years.
This is measured by assessing the proportion of children who have a suppressed Luteinizing
Hormone (LH) response to Gonadotropin Releasing Hormone (GnRH) test performed 3 months after
injection with triptorelin 11. 25 mg.
Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer [Recruiting]
The purpose of this study is to evaluate the effect of an initial hormonal treatment
gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and T2- ERG), in
patients with histologically confirmed and advanced stages of prostate cancer. Their
characteristics according to risk factors such as PSA, Gleason score will be determined at
baseline and 1, 3 and 6 month post-treatment.
Reports of Suspected Trelstar (Triptorelin) Side Effects
Hot Flush (3),
Initial Insomnia (2),
Vitamin D Deficiency (2),
Pruritus (2), more >>